A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer

Leukemia

Volumn 21, Issue 10, 2007, Pages 2181-2191

  Rabin, N ^a   Kyriakou, C ^a   Coulton, L ^b   Gallagher, O M ^b   Buckle, C ^b   Benjamin, R ^a   Singh, N ^c   Glassford, J ^a   Otsuki, T ^d   Nathwani, A C ^a   Croucher, P I ^b   Yong, Kwee L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE MARROW; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICAL BONE; DISEASE SEVERITY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICRO-COMPUTED TOMOGRAPHY; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TIBIA; TRABECULAR BONE; TUMOR XENOGRAFT; VERTEBRA; VIRAL GENE DELIVERY SYSTEM;

EID: 34548802420     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404814     Document Type: Article

References (40)

1. Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80 (8 Suppl): 1557-1563.
2. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88: 62-66.
3. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49 192-198.
4. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
5. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
7. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-11586.
8. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98: 3527-3533.
9. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
10. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96: 671-675.
11. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483.
12. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349 2483-2494.
13. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992-3996.
14. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540.
15. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108: 1833-1841.
16. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 1993; 53 1392-1396.
17. Allsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 1996; 87: 1495-1501.
18. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997; 90: 2437-2444.
19. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999;14: 256-263.
20. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908-2913.
21. Yata K, Yaccoby S. The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18: 1891-1897.
22. Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: A new monoclonal antibody for detecting plasma cell differentiation in routine sections.J Clin Pathol 1994; 47: 418-422.
23. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242-251.
24. Ahmed F, Ings SJ, Pizzey AR, Blundell MP, Thrasher AJ, Ye HT et al. Impaired bone marrow homing of cytokine-activated CD34+cells in the NOD/SCID model. Blood 2004; 103: 2079-2087.
25. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(ql3;q32). Br J Haematol 1989; 73: 199-204.
26. Kyriakou CA, Yong KL, Benjamin R, Pizzey A, Dogan A, Singh N et al. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFIk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med 2006; 8: 253-264.
27. Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 1997; 158: 3578-3586.
28. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287-289.
29. Sordillo EM, Pearse RN. RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 2003; 97 (3 Suppl): 802-812.
30. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97 (3 Suppl): 887-892.
31. Doran PM, Turner RT, Chen D, Facteau SM, Ludvigson. JM, Khosla S et al. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 2004; 32: 351-359.
32. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-250.
33. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
34. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
35. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313.
36. Koc ON, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999; 27: 1675-1681.
37. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-1247.
38. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-3608.
39. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
40. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192-199.